Cover Image
Market Research Report

Global Non-Small Cell Lung Cancer Drugs Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 806187
Published Content info 124 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Non-Small Cell Lung Cancer Drugs Market 2019-2023
Published: March 6, 2019 Content info: 124 Pages
Description

About this market

The increasing prevalence and incidence of non-small cell lung cancer are one of the primary factors driving the global non-small cell lung cancer drugs market growth. The growing risk factors such as cigarette smoking, air pollution, secondary smoking, and occupational exposure is increasing the incidence of non-small cell lung cancer across the world. This will lead to an increase in the demand for non-small cell lung cancer drugs. Technavio's analysts have predicted that the non-small cell lung cancer drugs market will register a CAGR of over 13% by 2023.

Market Overview

Strong drug pipeline and recent drug approvals

One of the growth drivers of the global non-small cell lung cancer drugs market is the strong drug pipeline and recent drug approvals. The development of new drugs and their approvals are helpful for the treatment of non-small lung cancer, which is expected to drive the market during the forecast period.

The high cost of treatment

One of the challenges in the growth of global non-small cell lung cancer drugs market is the high cost of treatment. Non-small cell lung cancer can be treated by surgery, chemotherapy, radiation therapy, targeted therapies, and immunotherapy which is very costly. Therefore, the high cost of treatment for non-small cell lung cancer will hamper the growth of the market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the non-small cell lung cancer drugs market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented and with the presence of several vendors. The vendors in the market are using predictive biomarkers for the development of cost-effective therapies with improved clinical benefits. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR30977

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Biologics - Market size and forecast 2018-2023
  • Small molecule targeted therapy - Market size and forecast 2018-2023
  • Chemotherapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

PART 15: EXPLORE TECHNAVIO

Back to Top